Table 3.
Differentially Regulated Gene Interaction Identified in Kegg Pathways
| Kegg term | Gene count | –LogP | Kegg term | Gene count | –LogP |
|---|---|---|---|---|---|
| ELT | |||||
| Focal adhesion | 12 | 2.78 | ARVC | 5 | 1.22 |
| ECM-receptor interaction | 8 | 2.94 | Small cell lung cancer | 5 | 1.10 |
| p53 signaling pathway | 6 | 1.99 | Oocyte meiosis | 5 | 1.07 |
| Calcium signaling pathway | 8 | 1.26 | 7 | 1.79 | |
| Dams | |||||
| Natural killer cell mediated cytotoxicity | 20 | 11.81 | Systemic lupus erythematosus | ||
| Graft vs. host disease | 13 | 9.06 | ECM-receptor interaction | 6 | 1.62 |
| Cytokine–cytokine receptor interaction | 21 | 7.33 | NOD-like receptor signaling pathway | 5 | 1.47 |
| Hematopoietic cell lineage | 9 | 3.63 | Antigen processing and presentation | 6 | 1.47 |
| Chemokine signaling pathway | 12 | 3.04 | p53 signaling pathway | 5 | 1.32 |
| Allograft rejection | 7 | 3.03 | Autoimmune thyroid disease | 5 | 1.27 |
| Type I diabetes mellitus | 7 | 2.84 | Oocyte meiosis | 6 | 1.11 |
| Circadian rhythm | 4 | 2.72 | T cell receptor signaling pathway | 6 | 1.07 |
| Toll-like receptor signaling pathway | 8 | 2.47 | CAMs | 7 | 1.07 |
| Cytosolic DNA-sensing pathway | 6 | 2.35 | |||
| Offspring | |||||
| Focal adhesion | 110 | 11.70 | Purine metabolism | 64 | 1.94 |
| Huntington’s disease | 99 | 9.65 | Nucleotide excision repair | 22 | 1.91 |
| ECM-receptor interaction | 49 | 6.31 | Glioma | 30 | 1.89 |
| Oxidative phosphorylation | 68 | 5.96 | Nonsmall cell lung cancer | 26 | 1.83 |
| Adherens junction | 44 | 5.37 | RNA polymerase | 15 | 1.68 |
| Alzheimer’s disease | 86 | 5.09 | Colorectal cancer | 37 | 1.60 |
| Ubiquitin mediated proteolysis | 68 | 5.08 | Propanoate metabolism | 16 | 1.60 |
| Regulation of actin cytoskeleton | 99 | 5.00 | SNARE interactions in vesicular transport | 19 | 1.55 |
| Axon guidance | 64 | 4.40 | mTOR signaling pathway | 25 | 1.54 |
| Endocytosis | 91 | 4.36 | Type II diabetes mellitus | 23 | 1.50 |
| Parkinson’s disease | 64 | 4.15 | Leukocyte transendothelial migration | 48 | 1.45 |
| Proteasome | 28 | 3.73 | B cell receptor signaling pathway | 34 | 1.41 |
| Viral myocarditis | 47 | 3.59 | Graft-vs.-host disease | 26 | 1.41 |
| Valine, leucine and isoleucine degradation | 27 | 3.46 | p53 signaling pathway | 30 | 1.41 |
| Small cell lung cancer | 43 | 3.44 | Long-term potentiation | 30 | 1.32 |
| Fc gamma R-mediated phagocytosis | 48 | 3.40 | Hypertrophic cardiomyopathy | 35 | 1.32 |
| Spliceosome | 58 | 3.39 | ErbB signaling pathway | 36 | 1.31 |
| Insulin signaling pathway | 62 | 3.03 | CAMs | 59 | 1.26 |
| Pancreatic cancer | 36 | 2.80 | Glycosylphosphatidylinositol-anchor biosynthesis | 13 | 1.22 |
| Renal cell carcinoma | 35 | 2.73 | |||
| Pyrimidine metabolism | 45 | 2.71 | Lysine degradation | 19 | 1.21 |
| Vascular smooth muscle contraction | 53 | 2.45 | Gap junction | 35 | 1.18 |
| Glutathione metabolism | 27 | 2.42 | Dilated cardiomyopathy | 37 | 1.16 |
| RNA degradation | 30 | 2.37 | (ARVC) | 31 | 1.16 |
| Tight junction | 58 | 2.33 | Aldosterone-regulated sodium reabsorption | 19 | 1.11 |
| Pathways in cancer | 124 | 2.30 | Natural killer cell mediated cytotoxicity | 47 | 1.10 |
| Prostate cancer | 41 | 2.23 | Cell cycle | 49 | 1.09 |
| Phosphatidylinositol signaling system | 35 | 2.13 | Fatty acid biosynthesis | 5 | 1.09 |
| Neurotrophin signaling pathway | 55 | 2.06 | GnRH signaling pathway | 38 | 1.04 |
| Chronic myeloid leukemia | 35 | 2.02 | Systemic lupus erythematosus | 40 | 1.03 |
| Apoptosis | 39 | 2.00 | |||
CAMs, cell adhesion molecules.